• Enkam presents new results at the Society for Neur
• Commercial Partnership with STEMCELL Technologies
• ENKAM Pharmaceuticals Engages The Sage Group as Ad
• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

Presentation at BIO-Europe, Dusseldorf, Germany

________________________________________________________________

Copenhagen, November 8 2006 - ENKAM Pharmaceuticals A/S, the Copenhagen-based biotechnology company focused on cancer and neurodegenerative diseases, announces that Dr Morten Albrechtsen, Chief Executive Officer, will give a corporate presentation at BIO-Europe 2006, the 12^th Annual International Partnering Conference, today at 10:00 (CET). The BIO-Europe conference is being held at The Congress Centre in Dusseldorf, Germany and is taking place from 6^th to 8^th November 2006.

Ends